Log in
Enquire now
‌

US Patent 9751907 Arbekacin derivative, and production and use thereof

Patent 9751907 was granted and assigned to Meiji Seika Pharma on September, 2017 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent
0

Patent attributes

Patent Applicant
Meiji Seika Pharma
Meiji Seika Pharma
0
Current Assignee
Meiji Seika Pharma
Meiji Seika Pharma
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
97519070
Patent Inventor Names
Nao Sano0
Makoto Oyama0
Toshiro Sasaki0
Takashi Murata0
Ayako Odagiri0
Hiroyasu Miwa0
Hisashi Kishi0
Date of Patent
September 5, 2017
0
Patent Application Number
148918380
Date Filed
May 29, 2014
0
Patent Primary Examiner
‌
Layla Berry
0
Patent abstract

It has been found that adding carbon dioxide or the like to a solution containing arbekacin free base makes it possible to produce arbekacin derivatives including arbekacin carbonate and carbamic acid of arbekacin. Moreover, it has been found that the arbekacin derivatives have a high stability, and that the use thereof enables efficient productions of highly-pure arbekacin free base and pharmaceutically acceptable salt thereof.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 9751907 Arbekacin derivative, and production and use thereof

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.